199 related articles for article (PubMed ID: 16027168)
1. Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression.
Ma L; Teruya-Feldstein J; Behrendt N; Chen Z; Noda T; Hino O; Cordon-Cardo C; Pandolfi PP
Genes Dev; 2005 Aug; 19(15):1779-86. PubMed ID: 16027168
[TBL] [Abstract][Full Text] [Related]
2. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2.
Manning BD; Logsdon MN; Lipovsky AI; Abbott D; Kwiatkowski DJ; Cantley LC
Genes Dev; 2005 Aug; 19(15):1773-8. PubMed ID: 16027169
[TBL] [Abstract][Full Text] [Related]
3. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis.
Kim MJ; Cardiff RD; Desai N; Banach-Petrosky WA; Parsons R; Shen MM; Abate-Shen C
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2884-9. PubMed ID: 11854455
[TBL] [Abstract][Full Text] [Related]
4. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.
Chen Z; Trotman LC; Shaffer D; Lin HK; Dotan ZA; Niki M; Koutcher JA; Scher HI; Ludwig T; Gerald W; Cordon-Cardo C; Pandolfi PP
Nature; 2005 Aug; 436(7051):725-30. PubMed ID: 16079851
[TBL] [Abstract][Full Text] [Related]
5. The role of PTEN in the progression and survival of prostate cancer.
Deocampo ND; Huang H; Tindall DJ
Minerva Endocrinol; 2003 Jun; 28(2):145-53. PubMed ID: 12717346
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions.
Latini JM; Rieger-Christ KM; Wang DS; Silverman ML; Libertino JA; Summerhayes IC
J Urol; 2001 Nov; 166(5):1931-6. PubMed ID: 11586263
[TBL] [Abstract][Full Text] [Related]
7. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression.
Kwabi-Addo B; Giri D; Schmidt K; Podsypanina K; Parsons R; Greenberg N; Ittmann M
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11563-8. PubMed ID: 11553783
[TBL] [Abstract][Full Text] [Related]
8. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice.
You MJ; Castrillon DH; Bastian BC; O'Hagan RC; Bosenberg MW; Parsons R; Chin L; DePinho RA
Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1455-60. PubMed ID: 11818530
[TBL] [Abstract][Full Text] [Related]
9. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse.
Di Cristofano A; De Acetis M; Koff A; Cordon-Cardo C; Pandolfi PP
Nat Genet; 2001 Feb; 27(2):222-4. PubMed ID: 11175795
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions.
Kaper F; Dornhoefer N; Giaccia AJ
Cancer Res; 2006 Feb; 66(3):1561-9. PubMed ID: 16452213
[TBL] [Abstract][Full Text] [Related]
11. Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis.
Velickovic M; Delahunt B; McIver B; Grebe SK
Mod Pathol; 2002 May; 15(5):479-85. PubMed ID: 12011252
[TBL] [Abstract][Full Text] [Related]
12. Genetic interactions between Pten and p53 in radiation-induced lymphoma development.
Mao JH; Wu D; Perez-Losada J; Nagase H; DelRosario R; Balmain A
Oncogene; 2003 Nov; 22(52):8379-85. PubMed ID: 14627978
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
[TBL] [Abstract][Full Text] [Related]
14. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
[TBL] [Abstract][Full Text] [Related]
15. Infrequent genetic alterations of the PTEN gene in Japanese patients with sporadic prostate cancer.
Orikasa K; Fukushige S; Hoshi S; Orikasa S; Kondo K; Miyoshi Y; Kubota Y; Horii A
J Hum Genet; 1998; 43(4):228-30. PubMed ID: 9852672
[TBL] [Abstract][Full Text] [Related]
16. Stem cells. PTEN--coupling tumor suppression to stem cells?
Penninger JM; Woodgett J
Science; 2001 Dec; 294(5549):2116-8. PubMed ID: 11739945
[No Abstract] [Full Text] [Related]
17. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.
Suzuki A; de la Pompa JL; Stambolic V; Elia AJ; Sasaki T; del Barco Barrantes I; Ho A; Wakeham A; Itie A; Khoo W; Fukumoto M; Mak TW
Curr Biol; 1998 Oct; 8(21):1169-78. PubMed ID: 9799734
[TBL] [Abstract][Full Text] [Related]
18. The biology and clinical relevance of the PTEN tumor suppressor pathway.
Sansal I; Sellers WR
J Clin Oncol; 2004 Jul; 22(14):2954-63. PubMed ID: 15254063
[TBL] [Abstract][Full Text] [Related]
19. PTEN/MMAC1/TEP1 involvement in primary prostate cancers.
Pesche S; Latil A; Muzeau F; Cussenot O; Fournier G; Longy M; Eng C; Lidereau R
Oncogene; 1998 Jun; 16(22):2879-83. PubMed ID: 9671408
[TBL] [Abstract][Full Text] [Related]
20. DNA mismatch repair deficiency accelerates endometrial tumorigenesis in Pten heterozygous mice.
Wang H; Douglas W; Lia M; Edelmann W; Kucherlapati R; Podsypanina K; Parsons R; Ellenson LH
Am J Pathol; 2002 Apr; 160(4):1481-6. PubMed ID: 11943731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
